NYSE:VRX - Valeant Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$23.40 0.00 (0.00 %)
(As of 07/17/2018 04:00 PM ET)
Previous Close$23.40
Today's RangeN/A
52-Week Range$10.94 - $27.79
Average Volume6.36 million shs
Market Capitalization$8.16 billion
P/E Ratio6.11
Dividend YieldN/A
Valeant Pharmaceuticals logoValeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.

Receive VRX News and Ratings via Email

Sign-up to receive the latest news and ratings for VRX and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NYSE
Industry Pharmaceutical preparations


Debt-to-Equity Ratio5.59
Current Ratio1.18
Quick Ratio0.92


Trailing P/E Ratio6.11
Forward P/E Ratio6.96
P/E Growth0.35

Sales & Book Value

Annual Sales$8.72 billion
Price / Sales0.94
Cash Flow$12.5134 per share
Price / Cash1.87
Book Value$17.05 per share
Price / Book1.37


EPS (Most Recent Fiscal Year)$3.83
Net Income$2.40 billion
Net Margins-10.65%
Return on Equity27.87%
Return on Assets3.58%


Outstanding Shares348,710,000
Market Cap$8,159.79

The Truth About Cryptocurrencies

Valeant Pharmaceuticals (NYSE:VRX) Frequently Asked Questions

What is Valeant Pharmaceuticals' stock symbol?

Valeant Pharmaceuticals trades on the New York Stock Exchange (NYSE) under the ticker symbol "VRX."

How were Valeant Pharmaceuticals' earnings last quarter?

Valeant Pharmaceuticals (NYSE:VRX) released its quarterly earnings data on Tuesday, May, 8th. The specialty pharmaceutical company reported $0.89 EPS for the quarter, topping the consensus estimate of $0.60 by $0.29. The specialty pharmaceutical company earned $2 billion during the quarter, compared to the consensus estimate of $1.95 billion. Valeant Pharmaceuticals had a positive return on equity of 27.87% and a negative net margin of 10.65%. Valeant Pharmaceuticals's revenue for the quarter was down 5.4% on a year-over-year basis. During the same period last year, the company earned $1.79 EPS. View Valeant Pharmaceuticals' Earnings History.

What price target have analysts set for VRX?

19 equities research analysts have issued 1 year price targets for Valeant Pharmaceuticals' stock. Their predictions range from $9.00 to $45.00. On average, they anticipate Valeant Pharmaceuticals' stock price to reach $21.5294 in the next twelve months. This suggests that the stock has a possible downside of 8.0%. View Analyst Ratings for Valeant Pharmaceuticals.

What is the consensus analysts' recommendation for Valeant Pharmaceuticals?

19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Valeant Pharmaceuticals in the last year. There are currently 4 sell ratings, 9 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Hold."

What are Wall Street analysts saying about Valeant Pharmaceuticals stock?

Here are some recent quotes from research analysts about Valeant Pharmaceuticals stock:
  • 1. HC Wainwright analysts commented, "Exchange NYSE Value (M) $31,421.0 Market Cap (M) $7,064 Public Market Float (M) 329.9 Shares Outstanding (M) 348.8 3 Interest (M) 40.90 Cash (M) $909.0 Total Debt (M) $25,266.0 Year – (0.25) FY 6.86 (7.48) (1.32) FY P/E 3.0x NM NM Year – 2,290.0 FY 8,724.0 8,325.0 8,810.0 30 25 20 15 10 0 Vol." (5/7/2018)
  • 2. According to Zacks Investment Research, "Valeant’s Bausch + Lomb/International segment and Salix businesses are doing well and should propel the top-line in the coming quarters. The approval of new drugs should boost the top line. After a tumultuous period, Valeant started a rebuilding process with its CEO, Joseph C. Papa. Shares of the company have outperformed the industry in the last six months. Even though it is still early to comment on the rebuilding process but the company’s efforts to sell non-core assets and pay lower debt is commendable. As of Feb 28, 2018, the company reduced total debt by approximately $6.7 billion since the end of first-quarter 2016. The dermatology business remains challenging and is expected to decline in 2018 as compared to 2017.  The guidance for 2018 was disappointing. Hence, it might be a while before the company turn arounds as management had projected." (4/2/2018)
  • 3. Cantor Fitzgerald analysts commented, "There has been some concern that VRX’s Xifaxan could face competition from Cosmo Pharmaceuticals (Not Covered) as early as 2019. We reiterate our Overweight rating and price target of $25; we don’t see fundamental reasons for the stock’s weakness this morning." (1/19/2018)

Who are some of Valeant Pharmaceuticals' key competitors?

Who are Valeant Pharmaceuticals' key executives?

Valeant Pharmaceuticals' management team includes the folowing people:
  • Mr. Joseph C. Papa, CEO & Chairman (Age 63)
  • Mr. Paul S. Herendeen, Exec. VP & CFO (Age 62)
  • Ms. Christina M. Ackermann, Exec. VP & Gen. Counsel (Age 53)
  • Mr. Thomas J. Appio, Exec. VP & Group Chairman of International (Age 56)
  • Mr. William D. Humphries, Exec. VP & Group Chairman of Dermatology (Age 52)

Has Valeant Pharmaceuticals been receiving favorable news coverage?

Press coverage about VRX stock has trended positive recently, according to Accern. Accern rates the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Valeant Pharmaceuticals earned a news sentiment score of 0.32 on Accern's scale. They also gave news articles about the specialty pharmaceutical company an impact score of 46.79 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Valeant Pharmaceuticals' major shareholders?

Valeant Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.94%), Assenagon Asset Management S.A. (0.38%), Montrusco Bolton Investments Inc. (0.06%), Fox Run Management L.L.C. (0.01%), Cohen Klingenstein LLC (0.00%) and Cito Capital Group LLC (0.00%). Company insiders that own Valeant Pharmaceuticals stock include Argeris N Karabelas, John Paulson, Joseph C Papa, Paul Herendeen, Pershing Square Capital Manage, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Institutional Ownership Trends for Valeant Pharmaceuticals.

Which institutional investors are selling Valeant Pharmaceuticals stock?

VRX stock was sold by a variety of institutional investors in the last quarter, including Montrusco Bolton Investments Inc. and Cito Capital Group LLC. View Insider Buying and Selling for Valeant Pharmaceuticals.

Which institutional investors are buying Valeant Pharmaceuticals stock?

VRX stock was bought by a variety of institutional investors in the last quarter, including Bank of Montreal Can, Assenagon Asset Management S.A., Fox Run Management L.L.C., Cohen Klingenstein LLC and Meag Munich Ergo Kapitalanlagegesellschaft MBH. Company insiders that have bought Valeant Pharmaceuticals stock in the last two years include Argeris N Karabelas, John Paulson, Joseph C Papa, Paul Herendeen, Schutter Richard U De, Thomas W Sr Ross and Valueact Capital Master Fund,. View Insider Buying and Selling for Valeant Pharmaceuticals.

How do I buy shares of Valeant Pharmaceuticals?

Shares of VRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Valeant Pharmaceuticals' stock price today?

One share of VRX stock can currently be purchased for approximately $23.40.

How big of a company is Valeant Pharmaceuticals?

Valeant Pharmaceuticals has a market capitalization of $8.16 billion and generates $8.72 billion in revenue each year. The specialty pharmaceutical company earns $2.40 billion in net income (profit) each year or $3.83 on an earnings per share basis. Valeant Pharmaceuticals employs 20,700 workers across the globe.

How can I contact Valeant Pharmaceuticals?

Valeant Pharmaceuticals' mailing address is 2150 ST. ELZEAR BLVD. WEST, LAVAL A8, H7L 4A8. The specialty pharmaceutical company can be reached via phone at 514-744-6792 or via email at [email protected]

MarketBeat Community Rating for Valeant Pharmaceuticals (NYSE VRX)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  1,287 (Vote Outperform)
Underperform Votes:  1,128 (Vote Underperform)
Total Votes:  2,415
MarketBeat's community ratings are surveys of what our community members think about Valeant Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/17/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.